The takeaway
An earlier mazdutide trial found meaningful average weight loss, but its short duration could not establish long-term benefits and risks.
Who was studied?
Researchers randomized 248 Chinese adults with overweight or obesity, without diabetes, to weekly mazdutide or placebo.
Percent of starting weight; modified intention-to-treat
Original visual based on the study.
| Group or measure | Result |
|---|---|
| Mazdutide 3 mg | −6.7% |
| Mazdutide 4.5 mg | −10.4% |
| Mazdutide 6 mg | −11.3% |
| Placebo | +1.0% |
What changed?
At 24 weeks, average weight changes were −6.7%, −10.4% and −11.3% with 3, 4.5 and 6 mg, respectively, versus +1.0% with placebo. Placebo participants gained weight on average. Missing measurements were handled by carrying forward earlier observations.
The trade-offs
Digestive symptoms were common. Nine mazdutide recipients had serious adverse events, versus none on placebo; investigators considered them unrelated to treatment. That assessment does not make a small trial proof of long-term safety.
The short follow-up and single-country population limit generalizability. This report covered the lower-dose part of a two-part trial; the 9 mg report is separate.
Innovent sponsored the study.